Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277702 | 0.92 | PBRM1 (0.44) | PLA2G7PBRM1MAPTMEN1TP53 | |
| SCHEMBL699897 | 0.86 | ALDH1A1 (0.46) | MAPTMEN1KMT2AS1PR4PDK2 | |
| SCHEMBL277658 | 0.81 | HSP90AA1 (0.47) | PBRM1MAPTMEN1KMT2AGRIA1 | |
| SCHEMBL277417 | 0.77 | PLA2G7 (0.49) | PLA2G7PBRM1MAPTMEN1TP53 | |
| SCHEMBL277830 | 0.76 | GRIA1 (0.47) | PBRM1MAPTMEN1TP53KMT2A | |
| SCHEMBL277914 | 0.76 | PLA2G7 (0.67) | PLA2G7MAPTMEN1TP53KMT2A | |
| SCHEMBL521542 | 0.75 | PLA2G7 (0.50) | PLA2G7PBRM1KMT2AGRIA1CACNG8 | |
| SCHEMBL14364369 | 0.73 | AQP1 (0.42) | PLA2G7RAB9A | |
| SCHEMBL10343150 | 0.73 | PLA2G7 (0.47) | PLA2G7MAPTMEN1TP53KMT2A | |
| SCHEMBL5281695 | 0.73 | PLA2G7 (0.47) | PLA2G7PBRM1KMT2APDK2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012254-A1 | BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS | Theravance Respiratory Company, LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2246345-B1 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE RESPIRATORY CO LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-8969571-B2 | Biphenyl derivatives | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8618131-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130150404-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8247564-B2 | Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8242135-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8143277-B2 | Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110312994-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2004106333-A1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242622-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004089892-A2 | DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| WO-2004074812-A2 | LIBRARY OF BIPHENYL DERIVATIVES USEFUL FOR IDENTIFYING COMPOUNDS HAVING BOTH BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074246-A2 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235864-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | PLA2G7 1006/4885PBRM1 1285/4885MAPT 3358/4885 |
| US-20040242622-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA1B | PLA2G7 1738/4885PBRM1 3419/4885MAPT 4287/4885 |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB1, ADRB2, ADRA2B | PLA2G7 1323/4885PBRM1 1771/4885MAPT 4588/4885 |
| US-20130150404-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | PLA2G7 995/4885PBRM1 1281/4885MAPT 3349/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | PLA2G7 726/4885PBRM1 3259/4885MAPT 3864/4885 |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRA2B, ADRB2, ADRB1 | PLA2G7 1851/4885PBRM1 2069/4885MAPT 2552/4885 |
| US-20110312994-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | PLA2G7 1006/4885PBRM1 1285/4885MAPT 3358/4885 |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | ADRA2C, ADRB2, AHR | PLA2G7 1075/4885PBRM1 2517/4885MAPT 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.